Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-03-01Actual
Enrollment · participants213Actual
Source updated2023-08-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.